Get the Stockscreener App
5.70
6.86%
-0.42
After Hours:
5.70
Ginkgo Bioworks Holdings Inc stock is traded at $5.70, with a volume of 1.30M.
It is down -6.86% in the last 24 hours and down -30.83% over the past month.
See More
Previous Close:
$6.12
Open:
$5.73
24h Volume:
1.30M
Relative Volume:
0.83
Market Cap:
$382.44M
Revenue:
$217.11M
Net Income/Loss:
$-651.19M
P/E Ratio:
-0.4388
EPS:
-12.99
Net Cash Flow:
$-387.26M
1W Performance:
-25.97%
1M Performance:
-30.83%
6M Performance:
-30.06%
1Y Performance:
-87.72%
1-Day Range:
$5.52
$5.88
1-Week Range:
$5.52
$7.7704
52-Week Range:
$5.26
$47.60
Ginkgo Bioworks Holdings Inc Stock (DNA) Company Profile
Name
Ginkgo Bioworks Holdings Inc
Sector
Industry
Phone
(877) 442-5362
Address
27 DRYDOCK AVENUE, BOSTON
Compare DNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DNA
Ginkgo Bioworks Holdings Inc
|
5.70 | 382.44M | 217.11M | -651.19M | -387.26M | -12.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Ginkgo Bioworks Holdings Inc Stock (DNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-15-24 | Downgrade | BTIG Research | Neutral → Sell |
| May-10-24 | Downgrade | William Blair | Mkt Perform → Underperform |
| Nov-14-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-09-23 | Downgrade | BTIG Research | Buy → Neutral |
| Jun-02-23 | Downgrade | Goldman | Neutral → Sell |
| May-11-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Nov-29-22 | Initiated | Berenberg | Buy |
| Oct-04-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-18-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-02-22 | Resumed | Cowen | Outperform |
| Feb-23-22 | Initiated | Goldman | Neutral |
| Feb-01-22 | Initiated | BofA Securities | Neutral |
| Jan-28-22 | Initiated | BofA Securities | Buy |
| Jan-07-22 | Initiated | BTIG Research | Buy |
| Nov-29-21 | Initiated | Jefferies | Buy |
| Oct-13-21 | Initiated | Raymond James | Outperform |
| Oct-12-21 | Initiated | William Blair | Outperform |
| Sep-20-21 | Initiated | HSBC Securities | Buy |
View All
Ginkgo Bioworks Holdings Inc Stock (DNA) Latest News
Ginkgo Bioworks Holdings, Inc. (DNA) Sees a More Significant Dip Than Broader Market: Some Facts to Know - MSN
Where are the Opportunities in (DNA) - news.stocktradersdaily.com
Largest borrow rate increases among liquid names - TipRanks
Ginkgo Bioworks Holdings, Inc. (DNA) Surpasses Market Returns: Some Facts Worth Knowing - MSN
(DNA) Technical Pivots with Risk Controls - Stock Traders Daily
After Plunging -52.33% in 4 Weeks, Here's Why the Trend Might Reverse for Ginkgo Bioworks (DNA) - Yahoo Finance
SBI Securities Co. Ltd. Acquires Shares of 2,905 Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - Defense World
Ginkgo Bioworks (DNA) Upgraded to Buy: Here's Why - MSN
Ginkgo Bioworks Partners with HaDEA in Up to €24 Million Consort - GuruFocus.com
Ginkgo Bioworks (DNA) Insider Trading Activity 2025 - MarketBeat
Ginkgo Bioworks CFO sells shares worth $6,102 - Investing.com India
Ginkgo Bioworks CFO sells shares worth $6,102 By Investing.com - Investing.com Australia
Ginkgo Bioworks executive sells shares for over $3k - Investing.com
Y Intercept Hong Kong Ltd Purchases New Position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - Defense World
(DNA) Pivots Trading Plans and Risk Controls - Stock Traders Daily
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Ginkgo Bioworks Holdings, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 18, 2022DNA - ACCESS Newswire
Global Microbial Fermentation Technology Market to Increase at a Steady Growth Rate of ~5% by 2032 | DelveInsight - GlobeNewswire Inc.
Global Microbial Fermentation Technology Market to Increase at a Steady Growth Rate of ~5% by 2032 | DelveInsight - GlobeNewswire
Top 5 Synthetic Biology Public Companies (March 2025) - Securities.io
These Analysts Think Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Sales Are Under Threat - Simply Wall St
Ginkgo Bioworks (DNA) Expected to Announce Earnings on Thursday - MarketBeat
Ginkgo Bioworks (NYSE:DNA) Shares Gap DownHere's What Happened - MarketBeat
Ginkgo Bioworks (NYSE:DNA) Posts Quarterly Earnings Results, Misses Expectations By $0.37 EPS - MarketBeat
Ginkgo Bioworks (NYSE:DNA) Posts Earnings Results - MarketBeat
DNA; SRNG Upcoming Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Ginkgo Bioworks Holdings Inc. (f/k/a Soaring Eagle Acquisition Corp.) Investors of Class Action and Deadline: January 18, 2022 - ACCESS Newswire
Ginkgo Bioworks Earnings Call: Mixed Sentiments and Strategic Moves - TipRanks
Ginkgo Bioworks Shrinks Office and Lab Footprint in Boston, Cambridge - Connect CRE
Ginkgo Bioworks: Revenue Struggles Continue - Seeking Alpha
2025 Is Make Or Break For Ginkgo Bioworks (NYSE:DNA) - Seeking Alpha
Ginkgo Bioworks Holdings Full Year 2024 Earnings: EPS Misses Expectations - Yahoo Finance
Ginkgo Bioworks: Key Takeaways from Q4 and Full-Year 2024 Earnings Report - HPBL
Cautious Outlook on Ginkgo Bioworks: Sell Rating Amid Financial and Strategic Concerns - TipRanks
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q4 2024 Earnings Call Transcript - Insider Monkey
Ginkgo Bioworks Holdings Inc (DNA) Q4 2024 Earnings Call Highlights: Strategic Restructuring ... By GuruFocus - Investing.com Canada
Ginkgo Bioworks Holdings, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q4 Loss, Misses Revenue Estimates - MSN
Ginkgo Bioworks Reports Improved Q4 2024 Results - TipRanks
Ginkgo subleases part of HQ, looks to address $65M of excess space - The Business Journals
Ginkgo Bioworks Holdings Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Ginkgo Bioworks Reports Fourth Quarter and Full Year 2024 Financ - GuruFocus.com
Ginkgo Bioworks Holdings, Inc. SEC 10-K Report - TradingView
Ginkgo Bioworks Holdings, Inc. Q4 Loss Narrows - Nasdaq
Ginkgo Bioworks Reports Fourth Quarter and Full Year 2024 Financial Results - Kilgore News Herald
Ginkgo Bioworks (DNA) to Release Quarterly Earnings on Tuesday - MarketBeat
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Ginkgo Bioworks Holdings, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 18, 2022 – DNA - ACCESS Newswire
Ginkgo Bioworks (NYSE:DNA) Trading Down 6.3%What's Next? - MarketBeat
Volta Labs enhances Ginkgo Bioworks sequencing workflow By Investing.com - Investing.com Canada
Ginkgo Bioworks Integrates Callisto For Difficult-To-Automate Ngs Processes In Their High-Throughput Lab - Marketscreener.com
Ginkgo Bioworks integrates Callisto for difficult-to-automate NGS processes in their high-throughput lab - Marketscreener.com
Ginkgo Bioworks integrates Callisto for difficult-to-automate NG - GuruFocus.com
Short Interest in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Rises By 5.4% - MarketBeat
Ginkgo Bioworks Holdings Inc Stock (DNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.05%
1.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):